Carvolix · EURONEXT:CVX
Carvolix — Investor Presentation (September 2026)
23 slides from Carvolix's investor presentation, Sep 16, 2026
Slide 1: A Revolution in Interventional Procedures with AI Driven Mini-Robots
A REVOLUTION IN INTERVENTIONAL PROCEDURES WITH AI DRIVEN MINI-ROBOTS TO REPLACE CARDIAC VALVES AND TREAT STROKE
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been prepared by Carvolix SA (“Carvolix” or the “Company”) for information purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities of the Company in the United States or in any j
Slide 3: Carvolix's mission: democratize complex life-saving procedures
Carvolix’s mission: democratize complex life-saving procedures to replace cardiac valves and treat stroke A plane “knows” its position on Earth thanks to satellites and GPS, enabling autopilot autonomous systems. Proprietary AI and real-time imaging enable Carvolix mini-robots to operate autonomousl
Slide 4: Carvolix: A revolution in cardiac valves and stroke care
Carvolix: A revolution in cardiac valves and stroke care Estimated addressable Market of €23B by 2030 Five2 product launches in <5 years We leverage AI1 to create autonomous Commercial proprietary AI platform Tavipilot FDA cleared and commercial in the US, our first AI software mini-robots for the b
Slide 5: Clinical unmet needs in cardiac valve replacement and stroke treatment
Clinical unmet needs in cardiac valve replacement and stroke treatment PROCEDURAL VARIABILITY OF THE LIMITED ACCESS TO COMPLEXITY OUTCOME TREATMENT Complex manual Few experts/operators 17% for TAVI1 procedures Long learning curve 5% for Stroke Tortuous brain anatomy Complications 4% Mitral VR2 No di
Slide 6: Addressing major health issues: replace heart valves and treat ischemic strokes
Addressing major health issues: replace heart valves and treat ischemic strokes HEART VALVE REPLACEMENT (TAVI1) ISCHEMIC STROKE 34M €8B → €14B #1 cause of death 12M €2.2B → €2.6B #2 #2 cause of death ca 3 people >65 have severe aortic stenosis Market by 2030 Cardiovascular diseases Ischemic strokes
Slide 7: A sustained cadence of product launches accelerates the path to commercial scale
A sustained cadence of product launches accelerates the path to commercial scale TAVIPILOT Software TAVIPILOT Robot KALIOS ARTEDRONE MITRAPILOT AI Software for real time intra - Autonomous robot for Adjustable ring to repair Autonomous robot for Physiological, minimally operative guidance of transca
Slide 8: Carvolix autonomous platform for structural heart - TAVIPILOT
Carvolix autonomous platform for structural heart - TAVIPILOT TA VIP IL O T A I S O F TW ARE* TA VIP IL O T R O B O T Intraoperative software based on proprietary AI and per- procedure imaging for TAVI Guided by TAVIPILOT AI Software Link Video – TAVIPILOT Software Link Video –TAVIPILOT Robot • Enab
Slide 9: Carvolix stroke treatment platform
Carvolix stroke treatment platform Artedrone: Solution Link Video Artedrone: Animal Lab Link Video - Artedrone Animal Labs mars 2025 Strictly private & confidential - Carvolix - 2026 Page | 9
Slide 10: A rich pipeline driving sustained growth and market leadership
A rich pipeline driving sustained growth and market leadership Five product launches in <5 years, creating a portfolio of autonomous and advanced therapies 2024 2025 2026 2027 2028 2029 2030 TAVIPILOT PLATFORM Software A Rich Pipeline Driving Sustained Growth and Market Leadership US Launch EU Launc
Slide 11: Executive management and board members
Executive management and board members Céline Buard Sébastien Ladet, Ph.D Christophe de Vregille Jorgen Hansen Head of marketing and CEO CFO Chief AI & Robotics Commercialization Former Strategy, Portfolio 30+ years of experience of Multiple experiences as CFO Sr director at Medtronic management in
Slide 12: Growing Carvolix into an independent commercial stage world leader
Growing Carvolix into an independent commercial stage world leader Commercialize directly in EU Drive adoption with Reimbursement and via partnership in US & innovative pricing model ROW Collect real world data to support Focus on Interventional Cardiologists both Pay per patient pricing inclusive o
Slide 13: Carvolix operational footprint
Carvolix operational footprint 5 115 Sites Full-time Employees Joint Venture 5000sqm 2200sqm Overall Surface Pilot Manufacturing France Strictly private & confidential - Carvolix - 2026 Page | 13
Slide 14: A target you can trust
A target you can trust Sharpens Improves Reduces visibility positioning complications TAVIPILOT Software enhances procedural visibility, enables precise millimetric positioning, and reduces depth-related complications, delivering measurably safer TAVI outcomes for patients while lowering hospital co
Slide 15: Tavipilot - Targeting of TAVI centers for US launch
Tavipilot - Targeting of TAVI centers for US launch Tier 1: >400 TAVI – ultra high volume (10 centers) Tier 2: 200-300 TAVI – high volume (26 centers) Tier 3: 100-200 – medium volume Tier 4: 0-100 – low volume Tier 1&2 perform 56% of total cases, Tier 3&4 44% (average is 120 TAVI/yr). Tiers 3&4 (800
Slide 16: Main areas to cover
Main areas to cover: Phase 1: North East & Mid-West; Phase 2: South & West coast PRIORITY 2: Mid West PRIORITY 1: North-East region 20-24% of volume 22-24% of volume & KOLs Search on-going PRIORITY 4: West coast 10-12% of volume TARGETS FOR TAVIPILOT 1. High volume centers for quick return on real-l
Slide 17: Tavipilot - A three phase Go-to-Market strategy
Tavipilot - A three phase Go-to-Market strategy Phase 1 Phase 2 Phase 3 Post Market feedback collection Focus Market Release Full Commercialization • 2-3 sites. Real life feedback collection to • Expand to a total of 4 key regions. • Secure commercialization with enhance value prop, Highly controlle
Slide 18: Tavipilot software: pricing and reimbursement
Tavipilot software: pricing and reimbursement REGULATORY 510K clearance July 2025, K243884 REIMBURSEMENT LANDSCAPE - US MS-DRG Description FY26 Medicare1 Private Payer2 266 Endovascular cardiac valve replacement and supplement procedures with MCC $44,595 $80k-$97k 267 Endovascular cardiac valve repl
Slide 19: Launch in Europe - 2027/2028
Launch in Europe - 2027/2028 CE mark expected end of Q4 2026 – launch expected in Q1 2027 Keep direct distribution in Europe • Phase 1: launch in 2 top areas: • Zone1: France • Zone 2: Germany • Phase 2: progressively extend to Austria, Switzerland, Belgium, Luxembourg Launch at major congresses in
Slide 20: Strategic Financial Plan: Fueling market access and industrialization
Strategic Financial Plan: Fueling market access and industrialization with disciplined capital deployment Expected sources of funding 2026 Monthly burn €2.8M Contemplated Equity Potential Financing Financing monetisation needs Until breakeven expected in 2029 Artus Urinary Sphincter Breakeven €10M P
Slide 21: Strong market validation for Carvolix: #1 European interventional MedTech
Strong market validation for Carvolix: #1 European interventional MedTech Share Price & Volume 6-Jul 2026: Promising clinical data on the TAVIPILOT 3,0 platform & launch of the commercialization €7,0 2,5 15-Jun 2026: Positive 3-year clinical €6.28 results for Kalios 2,0 Value traded (EURm) 2-Feb 202
Slide 22: 2026 - 2027 Expected Newsflow
2026 - 2027 Expected Newsflow Q3 2026 Q4 2026 H1 2027 Corporate • 2nd tranche of equity finaning Edwards • Equity funding • Full financial year results & URD LS & Truffle. publication • Half year financial results system Cardiac • Kalios acquisition by Edwards LS • TaviPS - Signing of first referenc
Slide 23: 200M people worldwide affected by cardiac valves
$23B+ 200M people addressable worldwide affected market in 2030 by cardiac valves 5 products diseases or strokes AI-driven mini- robotic platforms Nasdaq IPO Commercial Mid term target stage with first AI guidance software 1 or 2 successful products will ensure success Family of 50+ patents